SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-158417
Filing Date
2024-06-10
Accepted
2024-06-10 16:58:32
Documents
17
Period of Report
2024-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d851509d8k.htm   iXBRL 8-K 28403
2 EX-4.2 d851509dex42.htm EX-4.2 179922
3 EX-5.1 d851509dex51.htm EX-5.1 12211
4 EX-5.2 d851509dex52.htm EX-5.2 67333
8 GRAPHIC g851509g0610231735024.jpg GRAPHIC 1756
  Complete submission text file 0001193125-24-158417.txt   468913

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rprx-20240610.xsd EX-101.SCH 2857
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20240610_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20240610_pre.xml EX-101.PRE 10817
20 EXTRACTED XBRL INSTANCE DOCUMENT d851509d8k_htm.xml XML 3513
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 241033550
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)